



Combat Drugs Limited

Regd. Off: 9-109/9, Plot No.112, Road No.14, Gayatri Nagar, Bouduppall, R.R.District -500039, TS
Ph: +91-40-66200100 / 65523363 Url: www.combatdrugs.in Email: info@combatdrugs.in
CIN No:L24230TG1986PLC006781 GST:36AAACC8372L1ZB D.L.No:TG/15/04/2016-14766 /14767

14/12/2017

To,
The General Manager
Department of Corporate Services - CRD
Bombay Stock Exchange Limited
Phiroze Jeejeebhoy Towers
Dalal Street, Mumbai 400 001

Dear Sir,

Sub: Outcome of Board Meeting

This is to inform you that the Board of Directors, in their meeting held today, ie; 14th December, 2017, have take up the additional matters, considered and approved the following:

1. Approved the Incorporation of a Wholly Owned Subsidiary (WoS), in India, to diversify and expand its business in the vast Information Technology Segment. The necessary actions for the incorporation of the Wholly Owned Subsidiary will be taken up with immediate effect.
2. Approved the Shifting of the Registered Office of the company from its current location to the new leased premises situated at 4th Floor, Plot No. 94, Sagar Society, Banjara Hills, Road No.2, Hyderabad – 500034 at the earliest. However, the company will continue to use part of the old premises as a Godown to store its stocks and supplies.

We kindly request you to take the same on record.

Thanking You,
Yours Sincerely,
For **COMBAT DRUGS LIMITED**

Sushant Mohan Lal

DIRECTOR & COMPLIANCE OFFICER





Combat Drugs Limited

Regd. Off: 9-109/9, Plot No.112, Road No.14, Gayatri Nagar, Bouduppall, R.R.District -500039, TS
Ph: +91-40-66200100 / 65523363 Url: www.combatdrugs.in Email: info@combatdrugs.in
CIN No:L24230TG1986PLC006781 GST:36AAACC8372L1ZB D.L.No:TG/15/04/2016-14766 /14767

14/12/2017

To,
The General Manager
Department of Corporate Services - CRD
Bombay Stock Exchange Limited
Phiroze Jeejeebhoy Towers
Dalal Street, Mumbai 400 001

Dear Sir,

Sub: Outcome of Board Meeting – Quarterly Results – 30th September, 2017

Pursuant to Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform you that at the meeting of the Board of Directors of the company held today ie; 14th December, 2017, held at 2pm the Statement of Un-Audited Financial Results for the quarter ended 30th September, 2017 was approved and taken on record along with the Limited Review Report for the period as issued by the Statutory Auditors of the company, along with other matters.

Please find enclosed the following in respect of the above said:

1. Statement of Un-Audited Financial Results for the Quarter and Half year ended 30th September, 2017 along with the requisite enclosures.
2. Limited Review Report of the Auditors on Quarterly Financial Results.

We kindly request you to take the same on record.

Thanking You,
Yours Sincerely,
For **COMBAT DRUGS LIMITED**

Sushant Mohan Lal

DIRECTOR & COMPLIANCE OFFICER



COMBAT DRUGS LIMITED

Regd.off:9-109/9, P.No.112, Rd No.14, Gayatri Nagar, Boduppal, RR.Dist, Hyd-39 TS

(CIN NO. CL23230TG1986PLC006781)

Ph: 040-66200100

URL: www.combatdrugs.in

Mail: info@combatdrugs.in

UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER & HALF YEAR ENDED 30th SEPTEMBER 2017

(Rupees in lakhs)

Sl No	Particulars	Quarter Ended			Half year ended	
		30.09.2017	30.06.2017	30.09.2016	30.09.2017	30.09.2016
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited
I	Revenue from operations	-	3.59	9.85	3.59	12.92
II	Other Income	22.90	-	-	22.90	-
III	Total Income (I+II)	22.90	3.59	9.85	26.49	12.92
	Expenses					
	a. Cost of Material consumed	-	0.80	5.13	0.80	7.70
	b. Purchases of stock-in-trade	-	-	-	-	-
	c.Changes in Inventories of Finished goods, work in progress and stock in trade	-	-	-	-	-
	d. Employee benefits expenses	7.20	5.85	5.09	13.05	9.17
	e. Depreciation and amortisation expense	-	-	-	-	-
	f. Other Expenses	3.37	4.71	5.45	8.09	10.01
IV	Total Expenses	10.57	11.36	15.67	21.94	26.88
V	Profit/(Loss) before Exceptional items and tax (III-IV)	12.33	(7.77)	(5.82)	4.55	(13.96)
VI	Exceptional Items	-	-	-	-	-
VII	Profit/(Loss) before tax (V-VI)	12.33	(7.77)	(5.82)	4.55	(13.96)
VIII	Tax Expense					
	(1) Income Tax	-	-	-	-	-
	(2) Deferred tax	-	-	-	-	-
IX	Profit/(Loss) for the period (VII-VIII)	12.33	(7.77)	(5.82)	4.55	(13.96)
X	Other Comprehensive Income					
	A(i) Items that will not be re-classified to profit or loss (Net of Tax)	-	-	-	-	-
	B(i) Items that will be reclassified to profit or loss (Net of Tax)	-	-	-	-	-
XI	Total Comprehensive Income for the period (IX+X)	12.33	(7.77)	(5.82)	4.55	(13.96)
XII	Paid Up Equity Share Capital (FV of Rs 10 each)	800	800	800	800	800
XIII	Earnings per share (EPS)					
	(a) Basic	0.15	(0.10)	(0.07)	0.06	(0.17)
	(b) Diluted	0.15	(0.10)	(0.07)	0.06	(0.17)

Notes :

1 The above results have been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on 14.12.2017. The financial results for the Quarter and Six months ended September 30, 2017 has been subject to limited review by the Company's Statutory Auditors.

2 In terms of Sec.133 of the Companies Act, 2013, the Company has adopted Indian Accounting Standards (Ind AS) w.e.f., 1st April 2017 and accordingly these unaudited financial results have been prepared in accordance with the recognition and measurement principals laid down in Ind AS 34 'Interim Financial Reportign' and other accounting principles generally accepted in India.



3 In terms of the Circular No. CIR/CFD/FAC/62/2016, dt. 05.07.2016 of SEBI, the Ind AS compliant unaudited financial results for the Quarter and Half yearly ended September 30, 2016 have not been subject to limited review by Statutory Auditors.

4 There is possibility that these Quarter and Half yearly results may require adjustment before constituting the final Ind AS Financial Statements as of and for the year ending March 31st, 2018 due to changes in Financial reporting requirements arising from new or revised standards or interpretations issued by MCA or changes in use of 1 or more optional exemptions from full retrospective application as permitted under Ind AS 101.

5 Reconciliation between financial results as previously reported under IGAAP and Ind AS for the Quarter and Six months ended 30th September 2016 is given below:

Particulars	6 Months Ended 30.09.2016	Quarter Ended 30.09.2016
Net Profit/(loss) under previous IGAAP		
Adjustments as per Ind AS	-13.96	-5.82
Total Comprehensive Income under Ind AS	-13.96	-5.82

6 The Company has opted to avail the relaxation provided by SEBI with respect to requirements for submission of IND AS compliant financial results for the previous year ended March 31, 2017 and balance sheet as at March 31, 2017. Accordingly, the figures for the financial results for the previous year ended March 31, 2017 and Balance sheet as at March 31, 2017 have not been presented.

7 The Company is operating in only one segment i.e., Pharmaceuticals and hence segment reporting is not applicable.

For and on behalf of the Board of Directors


Manging Director

Hyderabad
14.12.2017

COMBAT DRUGS LIMITED (CIN NO. CL23230TG1986PLC006781)

Regd.off:9-109/9, P.No.112, Rd No.14, Gayatri Nagar, Boduppall, RR.Dist, Hyd-39 TS

Ph: 040-66200100 URL: www.combatdrugs.in Mail: info@combatdrugs.in

STATEMENT OF UNAUDITED ASSETS AND LIABILITIES AS ON 30.09.2017

(Amount in Lakhs)

Particulars	30.09.2017
I.ASSETS	
Non-current Assets	
(a) Financial Assets	
(i) Loans and Advances	221.47
(b) Other Non-current Assets	0.48
Current Assets	
(a) Inventories	6.22
(b) Financial Assets	
(i) Trade Receivables	32.37
(ii) Cash and Cash Equivalentts	0.98
(iii) Loans	1.00
(c) Other Current Assets	10.37
TOTAL	272.89
II. EQUITY & LIABILITIES	
Equity	
(a) Equity Share Capital	800.00
(b) Other Equity	(601.67)
Liabilities	
Non-current liabilities	
(a) Financial liabilities	
(i) Borrowings	7.10
Current Liabilities	
(a) Financial Liabilities	
(i) Trade Payables	47.55
(ii) Other Financial Liabilities	13.31
(b) Other Current Liabilities	6.60
TOTAL	272.89



M. ANANDAM & CO.,
CHARTERED ACCOUNTANTS

INDEPENDENT AUDITORS' REVIEW REPORT ON REVIEW OF INTERIM FINANCIAL RESULTS

To,

The Board of Directors of Combat Drugs Limited

We have reviewed the accompanying Statement of Unaudited Financial Results of Combat Drugs Limited for the Quarter and six months ended 30th September, 2017. This statement is the responsibility of the company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review. Attention is drawn to the fact that the figures for the corresponding quarter and six months ended 30th September, 2016 including the reconciliation of total comprehensive income under Indian Accounting Standards ("Ind AS") of that period ended with profit reported under previous generally accepted accounting principles ("GAAP") as reported in these financial results have been approved by the Company's Board of Directors but have not been subjected to review or audit.


We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated 5th July, 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place: Hyderabad

Date: 14th December, 2017

For M. Anandam & Co.,
Chartered Accountants
(FRN: 0001255)



B.V. Suresh Kumar

B.V. Suresh Kumar
Partner

Membership No.212187